Somatostatin is a peptide with a potent and broad antisecretory action, which makes it an
invaluable drug target for the pharmacological management of pituitary adenomas and …

Acromegaly is a chronic disease with increased morbidity and mortality, where usually
multiple treatment modalities are used. The somatostatin analogs (SSAs) are the mainstay of …

Pituitary adenomas are currently classified by histological, immunocytochemical and
numerous ultrastructural characteristics lacking unequivocal prognostic correlations. We …

Object The 2004 WHO classification of pituitary adenomas now includes an “atypical”
variant, defined as follows: MIB-1 proliferative index greater than 3%, excessive p53 …

Aim To gather data regarding factors predicting responsiveness to pasireotide in
acromegaly. Patients and methods SSTR2a, SSTR3, SSTR5, AIP, Ki-67 and the adenoma …

GH-secreting pituitary adenomas can be hypo-, iso-or hyperintense on T2-weighted MRI
sequences. We conducted the current multicenter study in a large population of patients with …

Purpose Biochemical control is the main determinant of survival, clinical manifestations and
comorbidities in acromegaly. Transsphenoidal selective adenomectomy (TSA) is the initial …

Background Targets of acromegaly treatment are normalization of biochemical values,
removal/reduction/stabilization of the pituitary mass, control of clinical activity and mortality …

Background and Aims Predictors of first-generation somatostatin receptor ligands (fgSRLs)
response in acromegaly have been studied for over 30 years, but they are still not …

BACKGROUND: Long-term remission rates from endoscopic transsphenoidal surgery for
acromegaly and their relationship to prognostic indicators of disease aggressiveness are not …